- Home
- Apac Natural Killer Nk Cell Therapeutics Market
APAC Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: September, 2022 | Report ID: CLS-501 | No of pages: 191 | Format:
Asia-Pacific natural killer (NK) cell therapeutics market is projected to register a CAGR of 43.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific natural killer (NK) cell therapeutics market are:
Increase in patient population with chronic diseases
Increasing investment in research and development
Increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
Market Players:
The key market players for Asia-Pacific natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 30 1.1 OBJECTIVES OF THE STUDY 30 1.2 MARKET DEFINITION 30 1.3 OVERVIEW OF ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30 1.4 LIMITATIONS 32 1.5 MARKETS COVERED 33 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 THERAPEUTICS LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 SECONDARY SOURCES 45 2.11 ASSUMPTIONS 45 3 EXECUTIVE SUMMARY 46 3.1 EPIDEMIOLOGY 52 3.2 PESTEL ANALYSIS 53 3.3 PORTERS FIVE FORCES MODEL 54 3.4 INDUSTRIAL INSIGHTS: 55 3.5 PIPELINE ANALYSIS 57 4 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 58 5 MARKET OVERVIEW 60 5.1 DRIVERS 62 5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 62 5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 62 5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 63 5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 63 5.2 RESTRAINTS 64 5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 64 5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 64 5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 65 5.3 OPPORTUNITIES 66 5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 66 5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 66 5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 67 5.4 CHALLENGES 67 5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 67 5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 68 5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 68 6 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 70 6.1 OVERVIEW 71 6.2 NK CELL THERAPIES 74 6.3 NK CELL DIRECTED ANTIBODIES 74 7 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 76 7.1 OVERVIEW 77 7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 80 7.3 BISPECIFIC ANTIBODIES 81 8 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 82 8.1 OVERVIEW 83 8.2 CANCER 86 8.2.1 SOLID TUMORS 87 8.2.2 HEMATOLOGIC MALIGNANCIES 87 8.2.2.1 MULTIPLE MYELOMA 88 8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 88 8.2.2.3 LYMPHOMA 88 8.2.2.4 OTHERS 88 8.2.3 OTHERS 88 8.3 IMMUNOPROLIFERATIVE DISORDERS 88 8.4 ACUTE INFECTIOUS DISEASES 89 8.5 GASTROINTESTINAL DISEASES 89 8.6 OTHERS 90 9 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 92 9.1 OVERVIEW 93 9.2 HOSPITALS 96 9.3 SPECIALTY CLINICS 96 9.4 RESEARCH & ACADEMIC INSTITUTES 97 10 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 99 10.1 OVERVIEW 100 10.2 HOSPITAL PHARMACIES 103 10.3 DIRECT TENDER 103 10.4 OTHERS 104 11 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 105 11.1 ASIA-PACIFIC 106 11.1.1 JAPAN 113 11.1.2 CHINA 115 11.1.3 AUSTRALIA 117 11.1.4 SOUTH KOREA 119 11.1.5 INDIA 121 11.1.6 SINGAPORE 123 11.1.7 MALAYSIA 125 11.1.8 THAILAND 127 11.1.9 INDONESIA 129 11.1.10 PHILIPPINES 131 11.1.11 VIETNAM 133 11.1.12 REST OF ASIA-PACIFIC 135 12 ASIA PACIFIC NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 136 12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 136 13 SWOT ANALYSIS 137 14 COMPANY PROFILE 138 14.1 MERCK KGAA 138 14.1.1 COMPANY SNAPSHOT 138 14.1.2 RECENT FINANCIALS 138 14.1.3 PRODUCT PORTFOLIO 139 14.1.4 RECENT DEVELOPMENTS 139 14.2 BRISTOL-MYERS SQUIBB COMPANY 141 14.2.1 COMPANY SNAPSHOT 141 14.2.2 RECENT FINANCIALS 141 14.2.3 PRODUCT PORTFOLIO 142 14.2.4 RECENT DEVELOPMENTS 142 14.3 GLYCOSTEM 144 14.3.1 COMPANY SNAPSHOT 144 14.3.2 PRODUCT PORTFOLIO 144 14.3.3 RECENT DEVELOPMENTS 144 14.4 INNATE PHARMA, INC. 146 14.4.1 COMPANY SNAPSHOT 146 14.4.2 REVENUE ANALYSIS 146 14.4.3 PRODUCT PORTFOLIO 147 14.4.4 RECENT DEVELOPMENTS 147 14.5 REGENERON PHARMACEUTICALS INC. 149 14.5.1 COMPANY SNAPSHOT 149 14.5.2 RECENT FINANCIALS 149 14.5.3 PRODUCT PORTFOLIO 150 14.5.4 RECENT DEVELOPMENTS 150 14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 151 14.6.1 COMPANY SNAPSHOT 151 14.6.2 RECENT FINANCIALS 151 14.6.3 PRODUCT PORTFOLIO 152 14.6.4 RECENT DEVELOPMENTS 152 14.7 INMUNEBIO 153 14.7.1 COMPANY SNAPSHOT 153 14.7.2 REVENUE ANALYSIS 153 14.7.3 PRODUCT PORTFOLIO 154 14.7.4 RECENT DEVELOPMENTS 154 14.8 KIADIS PHARMA 156 14.8.1 COMPANY SNAPSHOT 156 14.8.2 REVENUE ANALYSIS 156 14.8.3 PRODUCT PORTFOLIO 157 14.8.4 RECENT DEVELOPMENTS 157 14.9 ACEPODIA INC. 159 14.9.1 COMPANY SNAPSHOT 159 14.9.2 PRODUCT PORTFOLIO 159 14.9.3 RECENT DEVELOPMENTS 159 14.10 AFFIMED GMBH 161 14.10.1 COMPANY SNAPSHOT 161 14.10.2 RECENT FINANCIALS 161 14.10.3 PRODUCT PORTFOLIO 162 14.10.4 RECENT DEVELOPMENTS 162 14.11 BIOHAVEN PHARMACEUTICALS 164 14.11.1 COMPANY SNAPSHOT 164 14.11.2 REVENUE ANALYSIS 164 14.11.3 PRODUCT PORTFOLIO 165 14.11.4 RECENT DEVELOPMENTS 165 14.12 BRINK BIOLOGICS, INC. 166 14.12.1 COMPANY SNAPSHOT 166 14.12.2 PRODUCT PORTFOLIO 166 14.12.3 RECENT DEVELOPMENT 166 14.13 CYTOVIA THERAPEUTICS 167 14.13.1 COMPANY SNAPSHOT 167 14.13.2 PRODUCT PORTFOLIO 167 14.13.3 RECENT DEVELOPMENTS 167 14.14 EMERCELL 169 14.14.1 COMPANY SNAPSHOT 169 14.14.2 PRODUCT PORTFOLIO 169 14.14.3 RECENT DEVELOPMENTS 169 14.15 FATE THERAPEUTICS 170 14.15.1 COMPANY SNAPSHOT 170 14.15.2 REVENUE ANALYSIS 170 14.15.3 PRODUCT PORTFOLIO 171 14.15.4 RECENT DEVELOPMENTS 171 14.16 GAMIDA CELL 173 14.16.1 COMPANY SNAPSHOT 173 14.16.2 PRODUCT PORTFOLIO 173 14.16.3 RECENT DEVELOPMENTS 174 14.17 ICELL GENE THERAPEUTICS 175 14.17.1 COMPANY SNAPSHOT 175 14.17.2 PRODUCT PORTFOLIO 175 14.17.3 RECENT DEVELOPMENT 175 14.18 IMMUNITYBIO, INC. 176 14.18.1 COMPANY SNAPSHOT 176 14.18.2 REVENUE ANALYSIS 176 14.18.3 PRODUCT PORTFOLIO 177 14.18.4 RECENT DEVELOPMENTS 177 14.19 MULTIMMUNE GMBH 178 14.19.1 COMPANY SNAPSHOT 178 14.19.2 PRODUCT PORTFOLIO 178 14.19.3 RECENT DEVELOPMENTS 178 14.20 NEKTAR 179 14.20.1 COMPANY SNAPSHOT 179 14.20.2 REVENUE ANALYSIS 179 14.20.3 PRODUCT PORTFOLIO 180 14.20.4 RECENT DEVELOPMENTS 180 14.21 NKARTA, INC. 181 14.21.1 COMPANY SNAPSHOT 181 14.21.2 PRODUCT PORTFOLIO 181 14.21.3 RECENT DEVELOPMENTS 181 14.22 PERSONGEN BIOTHERAPEUTICS 183 14.22.1 COMPANY SNAPSHOT 183 14.22.2 PRODUCT PORTFOLIO 183 14.22.3 RECENT DEVELOPMENTS 183 14.23 PHIO PHARMACEUTICALS 185 14.23.1 COMPANY SNAPSHOT 185 14.23.2 PRODUCT PORTFOLIO 185 14.23.3 RECENT DEVELOPMENTS 185 15 QUESTIONNAIRE 187 16 RELATED REPORTS 191Segmentation
Short Description Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific) Industry Trends and Forecast to 2029 Market Definition: Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells. NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease. The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity. Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth. Market Segmentation: Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel. On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others. On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others. Market Players The key market players for natural killer (NK) cell therapeutics market are listed below: Merck KGaA Bristol-Myers Squibb Company Glycostem Kiadis Pharma Cytovia Therapeutics Nkarta, Inc. Nektar ImmunityBio, Inc. Brink Biologics, Inc. Biohaven Pharmaceuticals Fate Therapeutics EMERcell Phio Pharmaceuticals PersonGen BioTherapeutics Innate Pharma, Inc. INmuneBIO Gamida Cell Acepodia Inc. Affimed GmbH Multimmune GmbH iCell Gene Therapeutics Takeda Pharmaceutical Company Limited Regeneron Pharmaceuticals Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.